CTLA4 Agonist Therapy for Steroid-Resistant Checkpoint irAEs
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for immune-related adverse events (irAEs) induced by immune checkpoint inhibitors, such as myocarditis, are often ineffective and can lead to fatal outcomes, particularly in cases resistant to high-dose corticosteroids and other immunosuppressive drugs.
Innovation Solution
The use of abatacept, a CTLA4 agonist, to treat or prevent immune-mediated diseases such as myocarditis, pneumonitis, hepatitis, hypophysitis, adrenal adverse effects, myositis, and nephritis, by administering effective doses that inhibit T-cell co-stimulation and potentially combined with other immunosuppressants or plasmapheresis to manage severe adverse events.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high-dose corticosteroids and other immunosuppressive drugs are used to treat immune-related adverse events, then the immune system is suppressed to reduce inflammation, but treatment effectiveness is insufficient and fatal outcomes occur in resistant cases
Solution Approach 1:
Abatacept serves as an intermediary agent that specifically targets the CD28-B7 co-stimulatory pathway. By binding to B7 molecules on antigen-presenting cells, it prevents inappropriate T-cell activation without broadly suppressing the entire immune system, thereby treating resistant irAEs effectively while minimizing off-target effects
Solution Approach 2:
The invention changes the therapeutic parameter from broad immunosuppression (corticosteroids) to targeted co-stimulation blockade (abatacept). This parameter change involves shifting from non-specific immune suppression to specific modulation of T-cell activation signals, thereby improving treatment effectiveness in resistant cases
2Object-affected harmful factors
If broad immunosuppression is used to treat irAEs, then inflammation is reduced, but off-target effects and insufficient efficacy in severe cases occur
Solution Approach 1:
Abatacept applies local quality by specifically targeting the CD28-B7 interaction pathway rather than broadly suppressing all immune functions. This localized approach affects only the co-stimulatory signal required for T-cell activation, leaving other immune functions intact and reducing off-target effects
Solution Approach 2:
As an intermediary, abatacept selectively modulates the co-stimulatory pathway between antigen-presenting cells and T-cells. It acts as a precise mediator that blocks only the specific pathological interaction responsible for irAEs without disrupting other essential immune functions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Abatacept effectively reduces the severity and reverses life-threatening irAEs like myocarditis, myositis, and hepatitis, offering a targeted approach with minimal off-target effects, as demonstrated by clinical cases showing rapid improvement in symptoms and reduced markers of immune-induced disease.
Implementation Method 1
a CTLA4 agonist is a substance that binds to the same cellular receptors as the CTLA4 reference substance (in particular that binds to CD80 or CD86)
Data Source
AI summary
The invention relates to the use of CTLA4 agonist for treating or preventing adverse events in patient treated with an immune checkpoint inhibitor.